How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
45
TGTX Quote, Financials, Valuation and Earnings
Last price:
$29.44
Seasonality move
:
18.19%
Day range:
$29.25 - $30.33
52-week range:
$25.28 - $46.48
Dividend yield:
0%
P/E ratio:
10.59x
P/S ratio:
8.94x
P/B ratio:
7.69x
Volume:
1.8M
Avg. volume:
2.1M
1-year change:
-11.78%
Market cap:
$4.7B
Revenue:
$329M
EPS (TTM):
$2.78
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$193.8M | $0.36 | 61.33% | 950.39% | $44.86 |
|
AXSM
Axsome Therapeutics, Inc.
|
$191.4M | -$0.75 | 57.25% | -43.6% | $212.94 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.16 | 29.62% | 234.42% | $14.50 |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$33.3M | -$2.00 | 14.08% | -52.17% | $15.33 |
|
KRYS
Krystal Biotech, Inc.
|
$105.5M | $1.61 | 35.17% | 42.95% | $288.70 |
|
MNKD
MannKind Corp.
|
$99.9M | $0.03 | 30.05% | 17.65% | $9.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$29.43 | $44.86 | $4.7B | 10.59x | $0.00 | 0% | 8.94x |
|
AXSM
Axsome Therapeutics, Inc.
|
$184.25 | $212.94 | $9.3B | -- | $0.00 | 0% | 16.16x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.29 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.31x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$6.52 | $15.33 | $111.2M | -- | $0.00 | 0% | 0.39x |
|
KRYS
Krystal Biotech, Inc.
|
$279.24 | $288.70 | $8.1B | 41.88x | $0.00 | 0% | 22.32x |
|
MNKD
MannKind Corp.
|
$5.78 | $9.61 | $1.8B | 61.36x | $0.00 | 0% | 5.69x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
29.47% | -2.499 | 4.53% | 2.53x |
|
AXSM
Axsome Therapeutics, Inc.
|
74.78% | -0.062 | 3.58% | 1.45x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
KPTI
Karyopharm Therapeutics, Inc.
|
-269.68% | 0.321 | 345.14% | 0.89x |
|
KRYS
Krystal Biotech, Inc.
|
0.83% | -0.755 | 0.19% | 9.43x |
|
MNKD
MannKind Corp.
|
124.56% | -0.195 | 13.7% | 2.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics, Inc.
|
$133.6M | $29.4M | 79.79% | 145.71% | 18.16% | -$23.2M |
|
AXSM
Axsome Therapeutics, Inc.
|
$156.7M | -$32.9M | -82.07% | -327.97% | -19.26% | $988K |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
KPTI
Karyopharm Therapeutics, Inc.
|
$41.8M | -$15.2M | -1579.24% | -- | -34.56% | -$5.9M |
|
KRYS
Krystal Biotech, Inc.
|
$92.1M | $41.4M | 19.74% | 19.91% | 42.31% | $38M |
|
MNKD
MannKind Corp.
|
$61.9M | $18.8M | 24.75% | -- | 22.86% | $22.4M |
TG Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns TGTX or AXSM?
Axsome Therapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of -27.62%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Axsome Therapeutics, Inc.'s return on equity of -327.97%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M AXSMAxsome Therapeutics, Inc.91.62% -$0.94 $292.3M -
What do Analysts Say About TGTX or AXSM?
TG Therapeutics, Inc. has a consensus price target of $44.86, signalling upside risk potential of 52.42%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $212.94 which suggests that it could grow by 15.57%. Given that TG Therapeutics, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 AXSMAxsome Therapeutics, Inc.16 1 0 -
Is TGTX or AXSM More Risky?
TG Therapeutics, Inc. has a beta of 1.865, which suggesting that the stock is 86.494% more volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.438, suggesting its less volatile than the S&P 500 by 56.163%.
-
Which is a Better Dividend Stock TGTX or AXSM?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or AXSM?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are smaller than Axsome Therapeutics, Inc. quarterly revenues of $171M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Axsome Therapeutics, Inc.'s net income of -$47.2M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 8.94x versus 16.16x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.8.94x 10.59x $161.7M $390.9M AXSMAxsome Therapeutics, Inc.16.16x -- $171M -$47.2M
-
Which has Higher Returns TGTX or FOLD?
Amicus Therapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 10.24%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About TGTX or FOLD?
TG Therapeutics, Inc. has a consensus price target of $44.86, signalling upside risk potential of 52.42%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.47%. Given that TG Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is TGTX or FOLD More Risky?
TG Therapeutics, Inc. has a beta of 1.865, which suggesting that the stock is 86.494% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock TGTX or FOLD?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or FOLD?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 8.94x versus 7.31x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.8.94x 10.59x $161.7M $390.9M FOLDAmicus Therapeutics, Inc.7.31x -- $169.1M $17.3M
-
Which has Higher Returns TGTX or KPTI?
Karyopharm Therapeutics, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of -75.21%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Karyopharm Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M KPTIKaryopharm Therapeutics, Inc.94.93% -$3.82 -$72.8M -
What do Analysts Say About TGTX or KPTI?
TG Therapeutics, Inc. has a consensus price target of $44.86, signalling upside risk potential of 52.42%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $15.33 which suggests that it could grow by 135.17%. Given that Karyopharm Therapeutics, Inc. has higher upside potential than TG Therapeutics, Inc., analysts believe Karyopharm Therapeutics, Inc. is more attractive than TG Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 KPTIKaryopharm Therapeutics, Inc.3 1 0 -
Is TGTX or KPTI More Risky?
TG Therapeutics, Inc. has a beta of 1.865, which suggesting that the stock is 86.494% more volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.207, suggesting its less volatile than the S&P 500 by 79.284%.
-
Which is a Better Dividend Stock TGTX or KPTI?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or KPTI?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 8.94x versus 0.39x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.8.94x 10.59x $161.7M $390.9M KPTIKaryopharm Therapeutics, Inc.0.39x -- $44M -$33.1M
-
Which has Higher Returns TGTX or KRYS?
Krystal Biotech, Inc. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 81.15%. TG Therapeutics, Inc.'s return on equity of 145.71% beat Krystal Biotech, Inc.'s return on equity of 19.91%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M KRYSKrystal Biotech, Inc.94.21% $2.66 $1.1B -
What do Analysts Say About TGTX or KRYS?
TG Therapeutics, Inc. has a consensus price target of $44.86, signalling upside risk potential of 52.42%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $288.70 which suggests that it could grow by 3.39%. Given that TG Therapeutics, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe TG Therapeutics, Inc. is more attractive than Krystal Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 KRYSKrystal Biotech, Inc.11 0 0 -
Is TGTX or KRYS More Risky?
TG Therapeutics, Inc. has a beta of 1.865, which suggesting that the stock is 86.494% more volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.705%.
-
Which is a Better Dividend Stock TGTX or KRYS?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or KRYS?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. TG Therapeutics, Inc.'s net income of $390.9M is higher than Krystal Biotech, Inc.'s net income of $79.4M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while Krystal Biotech, Inc.'s PE ratio is 41.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 8.94x versus 22.32x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.8.94x 10.59x $161.7M $390.9M KRYSKrystal Biotech, Inc.22.32x 41.88x $97.8M $79.4M
-
Which has Higher Returns TGTX or MNKD?
MannKind Corp. has a net margin of 19.97% compared to TG Therapeutics, Inc.'s net margin of 9.72%. TG Therapeutics, Inc.'s return on equity of 145.71% beat MannKind Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics, Inc.82.59% $2.43 $860.9M MNKDMannKind Corp.75.4% $0.03 $181.4M -
What do Analysts Say About TGTX or MNKD?
TG Therapeutics, Inc. has a consensus price target of $44.86, signalling upside risk potential of 52.42%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 66.28%. Given that MannKind Corp. has higher upside potential than TG Therapeutics, Inc., analysts believe MannKind Corp. is more attractive than TG Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics, Inc.6 1 0 MNKDMannKind Corp.8 0 0 -
Is TGTX or MNKD More Risky?
TG Therapeutics, Inc. has a beta of 1.865, which suggesting that the stock is 86.494% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.
-
Which is a Better Dividend Stock TGTX or MNKD?
TG Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or MNKD?
TG Therapeutics, Inc. quarterly revenues are $161.7M, which are larger than MannKind Corp. quarterly revenues of $82.1M. TG Therapeutics, Inc.'s net income of $390.9M is higher than MannKind Corp.'s net income of $8M. Notably, TG Therapeutics, Inc.'s price-to-earnings ratio is 10.59x while MannKind Corp.'s PE ratio is 61.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics, Inc. is 8.94x versus 5.69x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics, Inc.8.94x 10.59x $161.7M $390.9M MNKDMannKind Corp.5.69x 61.36x $82.1M $8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
